TNNI3 and coronary artery disorder: 5) exhibiting excellent selectivity between AMI, other heart‐related disease such as VDH, CAD, and healthy group; 6) miR‐499‐5p was detectable in serum samples of healthy volunteers, which was ultralow or even undetectable in plasma from healthy group[46]; 7) first realizing the ultrasensitive and rapid quantification and monitoring of cTnI and miR‐499‐5p in untreated saliva, urine, and interstitial fluid; 8) cTnI and miR‐499‐5p in saliva were proved more effective (cTnI, peak at 2 h; miR‐499‐5p, peak at 2 h) than in serum samples(cTnI, peak at 12–24 h[47]; miR‐499‐5p, peak at 6–12 h[48]).